St. John's Wort

St. John's Wort (Hypericum perforatum) is a perennial flowering plant native to Europe and widely naturalized across North America and Australia, traditionally used in folk medicine for wound healing, nerve pain, and melancholy for over 2,000 years. It contains a complex mixture of bioactive constituents including naphthodianthrones (hypericin and pseudohypericin), phloroglucinols (hyperforin and adhyperforin), flavonoids (quercetin, kaempferol, rutin), biflavones (amentoflavone), and xanthones. Standardized extracts are commercially available in capsules, tablets, and tinctures, typically standardized to 0.3 percent hypericin or 3 to 5 percent hyperforin content. It has been used as a prescription medication in Germany since the 1980s and is one of the best-selling botanical supplements in the United States and Europe.

The pharmacological significance of St. John's Wort has been transformed by the discovery that hyperforin is a potent activator of the pregnane X receptor (PXR), a nuclear receptor that serves as the master regulator of drug-metabolizing enzyme expression in the liver and intestine. PXR activation by hyperforin at concentrations achievable with standard supplemental doses triggers transcriptional upregulation of CYP3A4 (the most abundant drug-metabolizing cytochrome P450, responsible for metabolism of approximately 50 percent of all prescription drugs), CYP2C9, CYP2C19, and the MDR1 gene encoding P-glycoprotein. The magnitude of CYP3A4 induction is comparable to rifampicin, the antibiotic used as a positive control for maximal CYP3A4 induction in pharmacokinetic studies. This explains why the drug interactions of St. John's Wort are not merely theoretical: they are clinically documented and in several cases have caused organ rejection, HIV treatment failure, and contraceptive failure.

The antidepressant mechanism of St. John's Wort involves multiple monoaminergic pathways. Hyperforin inhibits the neuronal reuptake of serotonin, dopamine, norepinephrine, GABA, and glutamate through a mechanism unlike any conventional antidepressant: rather than directly blocking the reuptake transporter protein, hyperforin modulates intracellular sodium conductance via activation of TRPC6 (transient receptor potential canonical 6) channels, raising intracellular sodium and reducing the electrochemical gradient that drives monoamine uptake. This transporter-independent mechanism may explain the unusually broad monoamine reuptake inhibition profile. Certain flavonoid constituents also provide weak MAO-A and MAO-B inhibition, further preserving synaptic monoamine concentrations. The anxiolytic component involves hyperforin modulation of GABA-A receptor chloride conductance, contributing to reduced neuronal excitability.

The clinical evidence for St. John's Wort in mild-to-moderate depression is substantial by botanical standards. The 2008 Cochrane review by Linde et al., which analyzed 29 randomized trials with 5,489 participants across Germany, Austria, and the United States, found St. John's Wort superior to placebo (RR 1.48 for response rate) and statistically equivalent to standard antidepressants including SSRIs and tricyclics in head-to-head comparisons, with significantly fewer adverse effects and treatment discontinuations. The two large NIMH-funded trials conducted in the United States (Hypericum Depression Trial Study Group, 2002, JAMA; Shelton et al., 2001, JAMA) did not find St. John's Wort superior to placebo, but these trials enrolled predominantly severely depressed patients in whom the evidence is weaker globally. The disconnect between the European and American trial results is likely explained by patient selection: European trials enrolled mild-to-moderate depression, consistent with the evidence base, while the NIMH trials enrolled moderate-to-severe depression. For the appropriate population, St. John's Wort has genuine antidepressant efficacy, but the drug interaction risk makes it clinically appropriate only for individuals on no other medications.

Mechanism of Action

PXR Activation and CYP Enzyme Induction

The defining pharmacological characteristic of St. John’s Wort is the activation of the pregnane X receptor (PXR, encoded by NR1I2) by hyperforin, the principal phloroglucinol constituent. PXR is a nuclear receptor that functions as a xenobiotic sensor: when activated by foreign chemicals, it heterodimerizes with the retinoid X receptor (RXR) and binds to PXR response elements in the promoter regions of drug-metabolizing genes, driving their transcriptional upregulation. Hyperforin activates PXR at EC50 values in the range of 23 to 27 nanomolar, a concentration achieved in hepatocyte nuclei at standard supplemental doses. The downstream transcriptional targets include CYP3A4 (the most abundant drug-metabolizing cytochrome P450, responsible for the first-pass metabolism of approximately 50 percent of all prescription medications), CYP2C9 (the primary enzyme metabolizing warfarin, NSAIDs, phenytoin, and losartan), CYP2C19, and the MDR1 gene encoding P-glycoprotein efflux transporter. The constitutive androstane receptor (CAR) is co-activated, extending induction to CYP2B6 and CYP2C8. The magnitude of CYP3A4 induction by therapeutic doses of St. John’s Wort is comparable to rifampicin, the antibiotic used as a positive control for maximal PXR activation in clinical pharmacokinetic studies. Induction is detectable within 24 to 48 hours of initiation and reaches maximum within 10 to 14 days of continuous supplementation.

P-Glycoprotein Efflux Transporter Induction

Beyond cytochrome P450 enzyme induction, PXR activation by hyperforin upregulates the expression of MDR1 (P-glycoprotein, ABCB1) in the intestinal epithelium and, to a lesser extent, the blood-brain barrier. P-glycoprotein is an ATP-dependent efflux pump that actively transports its substrates from the intracellular compartment back into the intestinal lumen or blood, reducing absorption and CNS penetration. For drugs that are both CYP3A4 substrates and P-glycoprotein substrates (a very common overlap, since PXR co-regulates both), St. John’s Wort produces a dual pharmacokinetic interaction: reduced intestinal absorption from P-glycoprotein efflux combined with accelerated hepatic first-pass metabolism from CYP3A4 induction. The clinical consequence is a particularly large reduction in systemic drug exposure. Digoxin, a P-glycoprotein substrate but not a CYP3A4 substrate, shows a 25 percent reduction in AUC from St. John’s Wort through the P-glycoprotein mechanism alone, demonstrating that the transporter effect is independently clinically significant.

Serotonergic and Monoaminergic Mechanisms

The antidepressant mechanism of St. John’s Wort involves a pharmacologically unusual approach to monoamine reuptake inhibition. Unlike SSRIs, SNRIs, and tricyclic antidepressants, which directly occupy and block the serotonin transporter (SERT/SLC6A4), norepinephrine transporter (NET/SLC6A2), or dopamine transporter (DAT/SLC6A3) protein binding sites, hyperforin modulates monoamine reuptake through activation of TRPC6 (transient receptor potential canonical 6) ion channels. TRPC6 activation raises intracellular sodium concentration, which reduces the inward electrochemical sodium gradient that thermodynamically drives monoamine transport into neurons, effectively slowing reuptake of serotonin, dopamine, norepinephrine, GABA, and glutamate simultaneously. This broad-spectrum monoamine-preserving mechanism differs fundamentally from any single approved antidepressant. Certain flavonoid constituents including amentoflavone provide weak competitive inhibition of MAO-A, further preserving synaptic serotonin and norepinephrine. The GABA-A receptor modulation by hyperforin contributes to anxiolytic and sedative effects that complement the antidepressant activity.

Epigenetic Modulation

Emerging research suggests that hypericin and hyperforin modulate epigenetic regulators in neuronal cells. Hypericin has been shown to influence histone deacetylase (HDAC) activity in neuroblastoma cell lines, and hyperforin has been reported to modulate DNA methylation patterns in hippocampal neurons in rodent depression models, potentially contributing to long-term adaptation of stress response gene expression. Quercetin, one of the prominent flavonoid constituents, is a known inhibitor of DNA methyltransferase 1 (DNMT1) and influences histone H3 acetylation at promoters of genes involved in neuronal plasticity. These epigenetic mechanisms are preliminary and have not been validated in human clinical studies, but they offer a potential explanation for why St. John’s Wort antidepressant effects may persist for several days to weeks after discontinuation beyond what the plasma half-life of hyperforin would predict.

Clinical Evidence

Depression: Efficacy in Mild-to-Moderate Presentations

The randomized controlled trial evidence for St. John’s Wort in mild-to-moderate depression is among the strongest for any botanical supplement. The definitive synthesis is the 2008 Cochrane review by Linde, Berner, and Kriston (PMID 18843608) covering 29 RCTs with 5,489 patients, which found St. John’s Wort extracts superior to placebo (relative risk for response 1.48, 95% CI 1.23 to 1.77) and statistically comparable to standard antidepressants in response rate, with significantly fewer adverse effects and treatment dropouts. The European trials, which enrolled patients with mild-to-moderate depression defined by Hamilton Depression Rating Scale scores of 14 to 25, consistently showed clinically meaningful response rates of 55 to 65 percent. The two large NIMH-funded American trials (Hypericum Depression Trial Study Group, 2002, JAMA, n=340; Shelton et al., 2001, JAMA, n=200) did not find superiority over placebo, but both enrolled patients with moderately severe depression, consistent with the finding that benefit is most reliable in the mild-to-moderate severity range. The evidence does not support use for severe depression.

Drug Interaction Management: The Central Clinical Concern

The dominant clinical challenge with St. John’s Wort is not establishing its efficacy but identifying which patients can safely use it. Given that CYP3A4 metabolizes approximately half of all prescription drugs and CYP2C9 metabolizes another 15 percent, the pool of individuals on no CYP3A4 or CYP2C9 substrate medications is relatively small. The interactions with cyclosporine and tacrolimus in transplant recipients, with indinavir and other antiretrovirals in HIV-positive patients, and with oral contraceptives have been most extensively documented. For practitioners, the key clinical message is that St. John’s Wort should be considered a moderate-to-high risk supplement for any patient on polypharmacy, and disclosure at every clinical encounter should be actively solicited.

Seasonal Affective Disorder

Smaller but consistent evidence supports St. John’s Wort for seasonal affective disorder (SAD). A randomized trial by Wheatley (1999, Pharmacotherapy, PMID 10400399, n=149) found a standardized St. John’s Wort extract (LI160, 900 mg per day) comparable to bright light therapy (10,000 lux for 30 minutes per day) over 8 weeks in SAD patients, with equivalent improvements in Hamilton Depression Rating Scale scores and no significant difference in response rates. The monoaminergic mechanism is consistent with the neurobiology of SAD, which involves reduced serotonergic tone during winter months.

Dosing Guidance

Standard dosing for depression is 300 mg of a 0.3 percent hypericin-standardized extract three times daily (900 mg total). Some European formulations use 600 mg of a 5 percent hyperforin extract twice daily (1,200 mg total), with comparable antidepressant outcomes. Low-hyperforin extracts (ZE117, below 0.1 percent hyperforin) at 250 mg twice daily have been studied as a lower-interaction-risk option but with potentially reduced efficacy. Antidepressant response requires 4 to 6 weeks of consistent dosing at therapeutic doses; a minimum 6-week trial at full dose should be completed before concluding non-response. After discontinuation, a 2-week washout period is required before initiating any sensitive CYP3A4 or CYP2C9 substrate at standard doses, because hepatic enzyme protein turnover requires this duration even after hyperforin plasma clearance.